Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra

Drug Profile

Research programme: dengue antibodies - Massachusetts Institute of Technology/Visterra

Alternative Names: Monoclonal antibodies against dengue - Visterra; VIS-513

Latest Information Update: 11 Sep 2015

Price : $50

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Massachusetts Institute of Technology; Visterra
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dengue

Most Recent Events

  • 09 Sep 2015 VIS 513 licensed to Serum Institute of India in India, Pakistan, Bangladesh, Nepal, Bhutan, Maldives and Sri Lanka
  • 02 Oct 2014 Preclinical trials in Dengue in USA (Parenteral)
  • 08 Sep 2014 Preclinical pharmacodynamics data in Dengue presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top